<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/style/rss/rss_feed.xsl" type="text/xsl" media="screen"?><?xml-stylesheet href="/style/rss/rss_feed.css" type="text/css" media="screen" ?><rss version="2.0"><channel><title>Clipmarks | BobbyDelray's clips</title><link>http://clipmarks.com/clipper/BobbyDelray/date/2008/5/1/</link><feedUrl>http://rss.clipmarks.com/clipper/BobbyDelray/date/2008/5/1/</feedUrl><ttl>15</ttl><description>Clip, tag and save information that's important to you. Bookmarks save entire pages...Clipmarks save the specific content that matters to you!</description><language>en-us</language><item><title>Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II t</title><link>http://clipmarks.com/clipmark/E4B12526-E1AF-472E-8EA2-15AE3BFB394E/</link><description>&lt;b&gt;clipped by:&lt;/b&gt; &lt;a href="http://clipmarks.com/clipper/BobbyDelray/"&gt;BobbyDelray&lt;/a&gt;&lt;br&gt;&lt;div border="2" style="margin-top: 10px; border:#000000 1px solid;" width="90%"&gt;&lt;div style="background-color:"&gt;&lt;div align="center" width="100%" style="padding:4px;margin-bottom:4px;background-color:#666666;overflow:hidden;"&gt;&lt;span style="color:#FFFFFF;font-weight:bold;"&gt;Clip Source: &lt;a style="color:#FFFFFF;" href="http://alzheimersreadingroom.blogspot.com/2008/05/efficacy-and-safety-of-tarenflurbil-in.html" title="http://alzheimersreadingroom.blogspot.com/2008/05/efficacy-and-safety-of-tarenflurbil-in.html"&gt;alzheimersreadingroom.blogspot.com&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding: 10px;"&gt;&lt;div style="text-align:left;"&gt;&lt;BLOCKQUOTE&gt;800 mg tarenflurbil twice per day was well tolerated for up to 24 months of treatment, with evidence of a dose-related effect on measures of daily activities and global function in patients with mild AD.&lt;/BLOCKQUOTE&gt;&lt;/div&gt;&lt;/div&gt;&lt;hr size="2" color="#666666" /&gt;&lt;div style="padding: 10px;"&gt;&lt;div style="text-align:left;"&gt;&lt;SPAN&gt;We will try to keep you posted when the Phase 3 trial begins. Feel free to subscribe to our email list if you would like to be notified.&lt;/SPAN&gt;&lt;/div&gt;&lt;/div&gt;&lt;hr size="2" color="#666666" /&gt;&lt;div style="padding: 10px;"&gt;&lt;div style="text-align:left;"&gt;&lt;CENTER&gt;&lt;A href="http://www.feedburner.com/fb/a/emailverifySubmit?feedId=644838&amp;loc=en_US"&gt;&lt;B&gt;Receive Notification via Email&lt;/B&gt;&lt;/A&gt;&lt;/CENTER&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br&gt;&lt;div style="margin-bottom: 40px;"&gt;Tags: &lt;a href="http://clipmarks.com/tags/tarenflurbil/" rel="tag"&gt;tarenflurbil&lt;/a&gt;, &lt;a href="http://clipmarks.com/tags/alzheimer's/" rel="tag"&gt;alzheimer's&lt;/a&gt;, &lt;a href="http://clipmarks.com/tags/clinical+trials/" rel="tag"&gt;clinical trials&lt;/a&gt;&lt;/div&gt;</description><clipSource>http://alzheimersreadingroom.blogspot.com/2008/05/efficacy-and-safety-of-tarenflurbil-in.html</clipSource><pubDate>Thu, 01 May 2008 18:08:27 GMT</pubDate></item></channel></rss>